These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 9329624

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The metabolic marker tumour pyruvate kinase type M2 (tumour M2-PK) shows increased expression along the metaplasia-dysplasia-adenocarcinoma sequence in Barrett's oesophagus.
    Koss K, Harrison RF, Gregory J, Darnton SJ, Anderson MR, Jankowski JA.
    J Clin Pathol; 2004 Nov; 57(11):1156-9. PubMed ID: 15509675
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003 Nov; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The tumor metabolome.
    Mazurek S, Eigenbrodt E.
    Anticancer Res; 2003 Jun; 23(2A):1149-54. PubMed ID: 12820363
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Plasma levels of HER-2/neu, tumor type M2 pyruvate kinase and its tyrosine-phosphorylated metabolite in advanced breast cancer.
    Lüftner D, Mazurek S, Henschke P, Mesterharm J, Schildhauer S, Geppert R, Wernecke KD, Possinger K.
    Anticancer Res; 2003 Jun; 23(2A):991-7. PubMed ID: 12820337
    [Abstract] [Full Text] [Related]

  • 16. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert UB.
    Anticancer Res; 1997 Jun; 17(4B):3031-3. PubMed ID: 9329593
    [Abstract] [Full Text] [Related]

  • 17. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR.
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Mar; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.